Office: Cambridge, MA

Executive Assistant:
Kayla Seaman
(617) 949-2179

Nicholas Galakatos, PhD
Managing Director

Nicholas Galakatos, PhD, has been Managing Director of Clarus Ventures since the firm's inception in 2005. Prior to Clarus, Dr. Galakatos was a General Partner at MPM Capital, a healthcare venture capital firm.  He has over 27 years of industry and investment experience in the healthcare sector. From 1997 to 2000, Dr. Galakatos was Vice President of New Business at Millennium Pharmaceuticals (presently Takeda) and a member of the Management Team. He is a founder of Millennium Predictive Medicine and TransForm Pharmaceuticals, where he was the Chairman and founding CEO. Prior to Millennium he was at Venrock Associates focusing on early stage biotechnology investments. Prior to Venrock he was Head of Molecular Biology Research at Novartis (formerly Ciba). Dr. Galakatos is currently a member of the Director’s Council of the Koch Institute at MIT, and the Genetics Advisory Council at Harvard Medical School.

Dr. Galakatos earned his PhD in Organic Chemistry from MIT and performed his post-doctoral studies at Harvard Medical School.


Current Board Seats

Catabasis Pharmaceuticals

Ophthotech (NASDAQ:OPHT)

Nanostring (NASDAQ:NSTG)

Portola (NASDAQ:PTLA)

Previous Board Seats

Affymax (NASDAQ: AFFY) - Lead Director

Aveo (NASDAQ:AVEO)

Hypnion (acquired by Eli Lilly) - Chairman

Caliper (NASDAQ:CALP)

Critical Therapeutics (NASDAQ:CRTX)

Link Medicine (acquired by AstraZeneca)

Millennium Biotherapeutics (acquired by Millennium)

Millennium Predictive Medicine (acquired by Millennium)

Syrrx (acquired by Takeda)

Taligen (acquired by Alexion)

Transform (acquired by J&J) - Chairman

Clarus Board Seats

Fund: Clarus Lifesciences II, L.P.
Sector: Biotechnology
Status: False
Type: Private
Team: Scott Requadt
Finny Kuruvilla
Nicholas Galakatos

Catabasis Pharmaceuticals, Inc.

Catabasis is an early stage biopharmaceutical company led by experienced entrepreneurs that is developing NCEs that incorporate, and amplify the beneficial effects of, OMEGA-3 fatty acids. It is advancing multiple proprietary small molecule candidates for the treatment of metabolic disease and inflammation.

Catabasis Website

Fund: Clarus Lifesciences II, L.P.
Sector: Biotechnology
Status: False
Type: Private
Team: Scott Requadt
Michael Steinmetz
Nicholas Galakatos
Fund: Clarus Lifesciences II, L.P.
Sector: Diagnostics & Tools
Status: False
Type: Public
Team: Finny Kuruvilla
William Young
Nicholas Galakatos

NanoString Technologies, Inc. (NASDAQ: NSTG)

Nanostring is a commercial stage company and an emerging leader in the expression profiling market. Its lead product is the only system capable of highly multiplexed direct quantification of individual mRNAs in a biological sample without the use of enzymes or amplification. With sensitivity below a single copy of mRNA per cell, high accuracy, robust output, and simplified workflow, the Nanostring platform offers investigators the benefits of the accuracy of PCR with the ability to interrogate more genes (up to a thousand) that would traditionally not be possible with PCR . Unlike PCR or microarrays, the Nanostring technology affords digital results by directly imaging and counting mRNAs on solid support.

NanoString Website

Fund: Clarus Lifesciences II, L.P.
Sector: Biotechnology
Status: False
Type: Public
Team: Nicholas Galakatos
Emmett Cunningham

Ophthotech Corporation (NASDAQ: OPHT)

Ophthotech Corporation is a privately-held, clinical-stage biotechnology company focused on developing and commercializing therapies for both wet and dry Age-Related Macular Degeneration (AMD). Three new molecular entities are currently in clinical development: E10030, an anti-platelet-derived growth factor (PDGF) pegylated aptamer; ARC1905, a pegylated aptamer targeting the C5 component of the complement cascade; and Volociximab, a monoclonal antibody targeting the transmembrane receptor α5β1 integrin. All three Ophthotech drug products are currently in a phase 1 clinical trial for combination treatment with anti-VEGF therapy (Lucentis®). The most advanced product, E10030, has completed a Phase 1 trial.

Ophthotech Website

Fund: Clarus Lifesciences I, L.P.
Sector: Biotechnology
Status: True
Type: Private
Team: Nicholas Galakatos
Emmett Cunningham

Taligen acquired by Alexion (ALXN) in January 2011

Taligen is a biopharmaceutical company focused on developing inhibitors of the complement system for a variety of therapeutic indications.

Taligen Website